Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 31, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with RYZB included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
Shares in RayzeBio (NASDAQ: RYZB ) doubled after Bristol Myers Squibb (NYSE: BMY ) said it will buy it for about $4.1 billion. Bristol Myers is paying $62.50 per share for the cancer drug maker, which is based in San Diego.
RayzeBio is a late-stage developer of radiotherapeutic products targeting solid tumors in oncology. Their lead asset, RYZ101, uses the 225Ac isotope to target gastroenteropancreatic neuroendocrine tumors (GEP-NETs) through the SSTR2 receptor. RYZ101 has shown promising results in a phase 1b study, with a confirmed overall response rate of 29% as of June 2023.
Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside. The company's radiopharmaceutical technology could revolutionize the cancer treatment landscape. RYZ801 has shown promise in GPC3 expressing hepatocellular cancers.
Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% above the initial public offering price. The company had raised $311 million as it sold 17.3 million shares in the IPO, up from an expected 14.4 million shares, with the IPO pricing at $18 a share, at the top of the expected range.
RayzeBio Inc shares are expected to begin trading on the Nasdaq after Friday's open as the radiopharmaceutical company's upsized initial public offering (IPO) priced at the top end of the expected range. The company announced that it has offered 17.28 million shares in the IPO, up from previous expectations of 14.4 million shares, priced at $18 per share to raise $311.0 million.
RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offering priced at the top end of the expected range. The company said it offered 17.28 million shares in the IPO, up from previous expectations of 14.4 million shares, to raise $311.0 million.
RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Phase 3 trial looks to raise up to about $238.2 million. A total of 14.4 million shares will be offered in the IPO, with the company offering 13.2 million shares and a selling shareholder offering 1.2 million shares.
FAQ
- What is the primary business of RayzeBio?
- What is the ticker symbol for RayzeBio?
- Does RayzeBio pay dividends?
- What sector is RayzeBio in?
- What industry is RayzeBio in?
- What country is RayzeBio based in?
- When did RayzeBio go public?
- Is RayzeBio in the S&P 500?
- Is RayzeBio in the NASDAQ 100?
- Is RayzeBio in the Dow Jones?
- When was RayzeBio's last earnings report?
- When does RayzeBio report earnings?
- Should I buy RayzeBio stock now?